Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
NEW BRUNSWICK, N.J., March 12/PRNewswire-FirstCall/ --Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for financial analysts on Sunday, March 15 at 10:00 a.m. (Eastern Time) to coincide with the World Institute of Pain 5th World Congress (WIP) in New York City. Phase 3 clinical data on investigational tapentadol extended release (ER), a novel centrally acting oral analgesic, will be presented for the first time in a poster session at WIP.
A pre-recorded Webcast, with the lead tapentadol researchers, will be made available concurrent to the data presentations being made during the poster session at WIP. Pre-registration is not required to view the webcast/podcast.
The presentation will provide an overview on tapentadol and review data from the following clinical posters:
Efficacy and Safety of Tapentadol Extended Release (ER) for Chronic Pain Due to Osteoarthritis of the Knee: Results of a Phase 3 Study
Efficacy and Gastrointestinal Tolerability of Tapentadol Extended Release in a Randomized, Double-Blind, Placebo- and Active-Controlled Study in Patients With Moderate-to-Severe Chronic Osteoarthritis Knee Pain
The webcast/podcast and replay can be accessed by clicking on "Webcasts/Presentations" in the Investor Relations section of the Company's website at http://www.jnj.com.
